Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban ...
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...
The Society of Interventional Radiology (SIR) published new practice guidance for the treatment of chronic pelvic pain in women who suffer from a pelvic venous disorder. The guidance was published ...
Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...
Society of Interventional Radiology publishes practice guidance for treatment of chronic pelvic pain
The Society of Interventional Radiology (SIR) published new practice guidance for the treatment of chronic pelvic pain in women who suffer from a pelvic venous disorder. The guidance was published ...
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs ...
The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and potentially reshape prescribing patterns in oncology and hematology.
Dayspring is a wearable non-pneumatic compression system that integrates static compression, sequential gradient compression, and muscle activation to support mobility during treatment. It is ...
The first clinical practice guideline on acute pulmonary embolism (PE) from the American Heart Association and the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results